ANDAs Must Include All Bioequivalence Data: FDA
The U.S. Food and Drug Administration issued a final rule Tuesday requiring pharmaceutical companies that apply to sell generic medications to provide data from all the bioequivalence studies they conduct on...To view the full article, register now.
Already a subscriber? Click here to view full article